ATE332303T1 - 2-substituierte hydroxy-2- indolinylbuttersäureesterverbindungen des s-typs und verfahren zu ihrer herstellung - Google Patents

2-substituierte hydroxy-2- indolinylbuttersäureesterverbindungen des s-typs und verfahren zu ihrer herstellung

Info

Publication number
ATE332303T1
ATE332303T1 AT02006610T AT02006610T ATE332303T1 AT E332303 T1 ATE332303 T1 AT E332303T1 AT 02006610 T AT02006610 T AT 02006610T AT 02006610 T AT02006610 T AT 02006610T AT E332303 T1 ATE332303 T1 AT E332303T1
Authority
AT
Austria
Prior art keywords
type
indolinyl
production
acid ester
ester compounds
Prior art date
Application number
AT02006610T
Other languages
English (en)
Inventor
Takayuki Kawaguchi
Sumihiro Nomura
Kenji Tsujihara
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of ATE332303T1 publication Critical patent/ATE332303T1/de

Links

Classifications

    • GPHYSICS
    • G02OPTICS
    • G02FOPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/133Constructional arrangements; Operation of liquid crystal cells; Circuit arrangements
    • G02F1/1333Constructional arrangements; Manufacturing methods
    • G02F1/1345Conductors connecting electrodes to cell terminals
    • G02F1/13452Conductors connecting driver circuitry and terminals of panels
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • GPHYSICS
    • G02OPTICS
    • G02FOPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/1303Apparatus specially adapted to the manufacture of LCDs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nonlinear Science (AREA)
  • Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mathematical Physics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02006610T 1996-10-30 1997-10-27 2-substituierte hydroxy-2- indolinylbuttersäureesterverbindungen des s-typs und verfahren zu ihrer herstellung ATE332303T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28807496 1996-10-30

Publications (1)

Publication Number Publication Date
ATE332303T1 true ATE332303T1 (de) 2006-07-15

Family

ID=17725479

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02006610T ATE332303T1 (de) 1996-10-30 1997-10-27 2-substituierte hydroxy-2- indolinylbuttersäureesterverbindungen des s-typs und verfahren zu ihrer herstellung
AT97308549T ATE247120T1 (de) 1996-10-30 1997-10-27 2-substituierte hydroxy-2- indolininylbluttersäureester des s-reihe als camptothecin-zwischnprodukte

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97308549T ATE247120T1 (de) 1996-10-30 1997-10-27 2-substituierte hydroxy-2- indolininylbluttersäureester des s-reihe als camptothecin-zwischnprodukte

Country Status (14)

Country Link
US (7) US5932732A (de)
EP (3) EP1236728B1 (de)
KR (5) KR100474496B1 (de)
CN (3) CN1077109C (de)
AT (2) ATE332303T1 (de)
CA (2) CA2533685C (de)
DE (2) DE69736308T2 (de)
DK (2) DK0845464T3 (de)
ES (2) ES2205134T3 (de)
HK (2) HK1050356B (de)
ID (1) ID18747A (de)
PT (2) PT1236728E (de)
SG (4) SG116433A1 (de)
TW (1) TW464652B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG116433A1 (en) * 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
CA2427467C (en) 2000-11-09 2010-01-12 Neopharm, Inc. Sn-38 lipid complexes and methods of use
US20090137816A1 (en) * 2000-12-15 2009-05-28 Kurt Baum Process for the manufacture of diaminofurazan
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
CN101337900B (zh) * 2001-02-21 2013-12-18 株式会社雅库路特本社 喜树碱相关化合物的合成方法
TWI245768B (en) 2001-02-21 2005-12-21 Yakult Honsha Kk Process for synthesizing camptothecin related compound(s)
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20040034050A1 (en) * 2002-06-03 2004-02-19 Yang Li-Xi Homo-camptothecin derivatives
AU2003243380A1 (en) * 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
CN100390177C (zh) * 2004-11-25 2008-05-28 复旦大学 6-氰基-7-甲基-1,1-(2,2-二甲基-1,3-亚丙二氧基)-5-氧-1,2,3,5-四氢吲哚哩啶(i)的制备方法
WO2007015259A2 (en) * 2005-08-03 2007-02-08 Avra Laboratories Pvt. Ltd. Method of synthesizing key intermediates for the production of camptothecin derivatives
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN104341429B (zh) * 2013-07-29 2016-08-10 北大方正集团有限公司 (s)-喜树碱中间体的制备方法及(s)-喜树碱的制备方法
IL277748B1 (en) * 2018-04-06 2024-03-01 Seagen Inc Camptothecin peptide conjugates
CN113041841B (zh) * 2021-03-22 2022-07-12 万华化学集团股份有限公司 一种抗污染浓水隔网的制备方法及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
JPS5711607A (en) * 1980-06-25 1982-01-21 Tokyo Shibaura Electric Co Movable shelf control apparatus
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP0220601B1 (de) * 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizinderivate und Verfahren zu ihrer Herstellung
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524803B2 (ja) * 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
ATE211142T1 (de) * 1989-09-15 2002-01-15 Res Triangle Inst Verfahren zur herstellung von 10,11-methylendioxy-20(rs)-camptothecin und 10,11-methylendioxy-20(s)-camptothecin-analog
TW201303B (de) * 1990-07-05 1993-03-01 Hoffmann La Roche
HU213136B (en) * 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP2923692B2 (ja) * 1990-11-30 1999-07-26 第一製薬株式会社 酵素による光学分割法
JP2887524B2 (ja) * 1990-11-30 1999-04-26 第一製薬株式会社 微生物による光学分割法
JPH04210675A (ja) * 1990-12-13 1992-07-31 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
CA2087898A1 (en) * 1992-01-24 1993-07-25 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
AU3611093A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation Substituted furo(3',4':6,7)indolizino(1,2-b)quinolinones
JP3126799B2 (ja) * 1992-03-31 2001-01-22 第一製薬株式会社 光学活性カンプトテシン誘導体及びその製法
JP3126798B2 (ja) * 1992-03-31 2001-01-22 第一製薬株式会社 光学活性インドリジン誘導体及びその製法
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
JPH07101956A (ja) * 1993-10-05 1995-04-18 Tanabe Seiyaku Co Ltd ヒドロキシカンプトテシン化合物の製法
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
IL117684A (en) * 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
WO1996036611A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
WO1997018194A1 (de) 1995-11-13 1997-05-22 Hoechst Aktiengesellschaft CYCLISCHE UND HETEROCYCLISCHE N-SUBSTITUIERTE α-IMINOHYDROXAM- UND CARBONSÄUREN
AU7732996A (en) 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
SG116433A1 (en) * 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren

Also Published As

Publication number Publication date
ES2205134T3 (es) 2004-05-01
PT845464E (pt) 2003-12-31
US6388078B1 (en) 2002-05-14
CN1077109C (zh) 2002-01-02
SG103322A1 (en) 2004-04-29
EP0845464A3 (de) 1999-06-23
US5932732A (en) 1999-08-03
EP0845464A2 (de) 1998-06-03
US6015901A (en) 2000-01-18
EP1236728A2 (de) 2002-09-04
KR100525025B1 (ko) 2005-10-31
TW464652B (en) 2001-11-21
HK1050356A1 (en) 2003-06-20
PT1236728E (pt) 2006-10-31
ES2267879T3 (es) 2007-03-16
ATE247120T1 (de) 2003-08-15
US6277992B1 (en) 2001-08-21
EP1236728B1 (de) 2006-07-05
DE69736308T2 (de) 2007-06-14
KR100653592B1 (ko) 2006-12-05
SG88737A1 (en) 2002-05-21
CA2533685A1 (en) 1998-04-30
SG116433A1 (en) 2005-11-28
KR20060086818A (ko) 2006-08-01
CA2219692C (en) 2007-05-22
US7060832B2 (en) 2006-06-13
KR19980033318A (ko) 1998-07-25
KR100578779B1 (ko) 2006-05-12
DK0845464T3 (da) 2003-12-01
US20030135049A1 (en) 2003-07-17
CN1313286A (zh) 2001-09-19
EP1236728A3 (de) 2002-12-18
EP1528062A2 (de) 2005-05-04
CA2219692A1 (en) 1998-04-30
CN1183414A (zh) 1998-06-03
DK1236728T3 (da) 2006-10-30
EP1528062A3 (de) 2007-02-07
DE69724081T2 (de) 2004-06-09
KR100474496B1 (ko) 2005-09-30
ID18747A (id) 1998-05-07
DE69736308D1 (de) 2006-08-17
US20020161231A1 (en) 2002-10-31
CN100528879C (zh) 2009-08-19
US6716983B2 (en) 2004-04-06
DE69724081D1 (de) 2003-09-18
EP0845464B1 (de) 2003-08-13
KR100567957B1 (ko) 2006-04-05
SG104284A1 (en) 2004-06-21
CN100473654C (zh) 2009-04-01
CA2533685C (en) 2009-05-26
HK1011538A1 (en) 1999-07-16
HK1050356B (zh) 2007-01-19
CN1915995A (zh) 2007-02-21
MX9708343A (es) 1998-08-30
US6114529A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
ATE332303T1 (de) 2-substituierte hydroxy-2- indolinylbuttersäureesterverbindungen des s-typs und verfahren zu ihrer herstellung
PH25423A (en) Method of treating bacterial infections using benzoxazine carboxylic acid
DE3876583D1 (de) Chinolincarbonsaeure-borsaeure-anhydride und verfahren zur herstellung.
ATE124687T1 (de) Verfahren zur herstellung von chinolincarbonsäuren.
ATE402940T1 (de) Verfahren zur herstellung von 3-cephem- verbindungen
DE69014730T2 (de) (1,2,3,4-Tetrahydro-9-acridinimino)cyclohexan-Carbonsäure und verwandte Verbindungen, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
ATE231858T1 (de) Verfahren zur herstellung von 3-substituierten 4- phenyl-piperidin derivaten
ATE336482T1 (de) Zwischenprodukte zur synthese von benzimidazolverbindungen und ein verfahren zu ihrer herstellung
ATE205211T1 (de) Benzopyranopyridoncarbonsäuren und verfahren zu ihrer herstellung
ATE156477T1 (de) Verfahren zur enantioselektiven synthese von 2(r)-benzylbernsteinsäuremonoamid-derivaten
GR3002020T3 (en) Carboxylic acid synthesis process
ATE179417T1 (de) Glyceraldehyd-3-pentanid und verfahren zu ihrer herstellung
ATE299147T1 (de) Verfahren zur herstellung von 3-amino-1,5- benzodiazepinderivaten
DE69706632D1 (de) Verfahren zur herstellung von 3-norcephem-verbindungen
DE69409776T2 (de) Verfahren zur Herstellung Pyridin-2,3-dicarboxylicsäure
DE3765810D1 (de) Verfahren zur herstellung von 1h-pyrrolizin-3,5-(2h,6h)-dionen.
DE69416117D1 (de) Verfahren zur herstellung von kondensierten carbapenemderivaten
ATE169908T1 (de) Verfahren zur herstellung von gegebenenfalls 2- substituierten 5-chlorimidazol-4-carbaldehyden
DE60315962D1 (de) Verfahren zur herstellung optisch aktiver verbindungen
DE69716370T2 (de) Verfahren zur herstellung von beta-lactam verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1236728

Country of ref document: EP

REN Ceased due to non-payment of the annual fee